Generic Name
Tiotropium Therapeutic Class: Anticholinergic Bronchodilators
Indications:
Tiotropium is indicated for the long-term once-daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Tiotropium reduces the frequency of exacerbations and improves exercise tolerance and health-related quality of life.
Presentation:
Tiotropium: Each capsule contains Tiotropium Bromide Monohydrate BP equivalent to 18 µg of Tiotropium.
Description:
Tiotropium is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3- receptors at the smooth muscle results in relaxation. The high potency and slow receptor dissociation found its clinical correlate insignificant and long-acting bronchodilation in patients with COPD.
Dosage & Administration:
The recommended dosage of Tiotropium is the inhalation of the contents of one capsule once daily with the ConviHaler device at the same time of day.
Side Effects:
Inhaled medicines may cause inhalation-induced bronchospasm, dehydration, dry mouth, constipation, dizziness, insomnia, skin, and subcutaneous tissue disorders, and immune system disorders
Precautions:
Tiotropium, as a once-daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of Tiotropium inhalation powder. As with other anticholinergic drugs, Tiotropium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction.
Use in Pregnancy & Lactation:
Pregnancy: There is a limited amount of data from the use of Tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses.
Lactation: Clinical data from nursing women exposed to Tiotropium are not available. Based on lactating rodent studies, a small amount of Tiotropium is excreted in milk. Therefore, Tiotropium should not be used in nursing women unless the expected benefit outweighs any possible risk to the unborn child or the infant.
Interaction:
Although no formal drug interaction studies have been performed, Tiotropium inhalation powder has been used concomitantly with other drugs, commonly used in the treatment of COPD, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids without clinical evidence of drug interactions.
Overdose:
High doses of Tiotropium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 282 micrograms of Tiotropium in healthy volunteers.
Storage:
Tiotropium is indicated for the long-term once-daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Tiotropium reduces the frequency of exacerbations and improves exercise tolerance and health-related quality of life.
Presentation:
Tiotropium: Each capsule contains Tiotropium Bromide Monohydrate BP equivalent to 18 µg of Tiotropium.
Description:
Tiotropium is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3- receptors at the smooth muscle results in relaxation. The high potency and slow receptor dissociation found its clinical correlate insignificant and long-acting bronchodilation in patients with COPD.
Dosage & Administration:
The recommended dosage of Tiotropium is the inhalation of the contents of one capsule once daily with the ConviHaler device at the same time of day.
Side Effects:
Inhaled medicines may cause inhalation-induced bronchospasm, dehydration, dry mouth, constipation, dizziness, insomnia, skin, and subcutaneous tissue disorders, and immune system disorders
Precautions:
Tiotropium, as a once-daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of Tiotropium inhalation powder. As with other anticholinergic drugs, Tiotropium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction.
Use in Pregnancy & Lactation:
Pregnancy: There is a limited amount of data from the use of Tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses.
Lactation: Clinical data from nursing women exposed to Tiotropium are not available. Based on lactating rodent studies, a small amount of Tiotropium is excreted in milk. Therefore, Tiotropium should not be used in nursing women unless the expected benefit outweighs any possible risk to the unborn child or the infant.
Interaction:
Although no formal drug interaction studies have been performed, Tiotropium inhalation powder has been used concomitantly with other drugs, commonly used in the treatment of COPD, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids without clinical evidence of drug interactions.
Overdose:
High doses of Tiotropium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 282 micrograms of Tiotropium in healthy volunteers.
Storage:
- Store below 25ºC but do not freeze.
- Store in a cool and dry place, protected from light.